PV Bulletin

Order Providing for Reliance on Foreign Regulatory Authority Decisions for Certain Drugs (Ministerial Reliance Order)

Health Canada introduced the Ministerial Reliance Order allowing the use of foreign regulatory data in drug submissions.

Primary source: The Ministerial Reliance Order: About the Order - Canada.ca

PV Impact Brief

Urgency: HighConfidence: high

What changed

Health Canada established a legal framework that allows reliance on foreign regulatory assessments for designated drug classes, making safety and efficacy requirements contingent on verified foreign data.

Why it matters

This Order enhances efficiency in drug approvals in Canada, encourages more submissions, and fosters collaboration with international regulatory bodies, potentially increasing drug availability in the Canadian market.

Action needed

Manufacturers must demonstrate that any variances from the foreign authorized drugs do not adversely affect safety or effectiveness when filing for deeming under this new framework.

Relevant for
Regulatory Intelligence LeadSignal Management LeadQPPV
Processes impacted
Country ComplianceSignal Management
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Draft Guidance
Policy status
Consultation
Publication date
2026-07-15
Consultation deadline
2026-09-12
Policy change
Operationalizes the Ministerial Reliance Order by describing evidentiary expectations, eligibility criteria, and manufacturer responsibilities for seeking deeming based on foreign authorizations.

Key changes

Outlines scenarios for reliance: general deeming, 120-day filing, and joint reviews. Specifies requirements for demonstrating safety comparability.

Affected workflows

Country ComplianceSignal Management

PV impact

Details the process for using foreign Risk Management Plans (RMPs) and safety data to satisfy Canadian requirements, provided the MAH justifies the applicability of foreign data to the Canadian context.

View regulator source

Source document details

Exact policy details

Regulatory requirements for filing
Complete regulatory submission must be filed in accordance with applicable filing requirements under the Food and Drug Regulations.
Applies to: Manufacturers filing human or veterinary new drug submissions, abbreviated new drug submissions, or supplements in Canada.
Source document states: 'A manufacturer must submit a complete regulatory submission in accordance with applicable filing requirements under the Food and Drug Regulations.' · p. 1 · High · Source
Conditions for deeming under the Order
The proposed Canadian drug must have the same strength, dosage form, route of administration, and medicinal ingredients as the foreign drug.
Applies to: Manufacturers seeking deeming under the Ministerial Reliance Order.
Source document states: 'Manufacturers must demonstrate that: the proposed Canadian drug has the same strength, dosage form, route of administration and medicinal ingredients as the foreign drug.' · p. 1 · High · Source

Workflow rule impacts

Country ComplianceHealth Canada review teams

Potential to simplify submissions by removing the need for certain examinations.

Inclusion of reliance on foreign regulatory authority documents.

Source document expresses intent to improve efficiency and reduce duplication in the review process. · p. 1 · High · Source

Extracted documents

Evidence and confidence

Confidence: highSource updated: Jul 15, 2026

Full briefing

Practical implication

Manufacturers must demonstrate that any variances from the foreign authorized drugs do not adversely affect safety or effectiveness when filing for deeming under this new framework.

The Ministerial Reliance Order, effective July 15, 2026, permits Health Canada to accept certain drug submissions based on decisions or documents from foreign regulatory authorities. This aims to streamline the review process for new drug submissions (NDS), abbreviated NDS (ANDS), supplements to NDS (SNDS), and supplements to ANDS (SANDS) while ensuring drug safety and efficacy standards are met.

What changed: Health Canada established a legal framework that allows reliance on foreign regulatory assessments for designated drug classes, making safety and efficacy requirements contingent on verified foreign data.

Why it matters: This Order enhances efficiency in drug approvals in Canada, encourages more submissions, and fosters collaboration with international regulatory bodies, potentially increasing drug availability in the Canadian market.

Practical implication: Manufacturers must demonstrate that any variances from the foreign authorized drugs do not adversely affect safety or effectiveness when filing for deeming under this new framework.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Safety Signals#Regulation#effective#Health Canada#guidance#policy-change#firecrawl-policy-agent

Related updates for your role

publicFood and Drug Administration (FDA) · United States · Updated Jun 29, 2026

eMDR System Enhancements - Production Deployment

Urgency: High

Update electronic safety reporting systems and pharmacovigilance databases to implement new rules to ensure all submissions use GENC 3-letter country codes and include the required fields as of July 20, 2026.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Urgency: High

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Urgency: High

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Agenda
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward